InvestWiser

Zealand Pharma A/S

ZEALNasdaq CopenhagenHealthcareMarket value 13.9 bn DKK
209.80DKK −1.4%
last day · Price as of 20 November 2026

The answer first

Does Zealand Pharma beat the market?

No, Zealand Pharma has not beaten the market over the last year.

Zealand Pharma−61.6%København (OMXCGI)+13.7%
  • The ranking · Quality, value and trend combined

    Better than 73% of Nordic stocks

    • Quality95
    • Value85
    • Trend7

    No. 33 of 195 in healthcare

Max for seven days

Follow Zealand Pharma with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 20 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Zealand Pharma

From today, at a price of 209.80 DKK. Write why you follow Zealand Pharma, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Zealand Pharma

Your first answer is free, no account needed.

Do you own Zealand Pharma, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Zealand Pharma and a few more. Free, no card.

Past year against the exchange and Super Stock
Zealand Pharma−58.1%København (OMXCGI)+13.7%Super Stock+45.3%
18 November 202520 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Zealand Pharma has fallen 61.6% over the past year, including dividends.
  • Overall, Zealand Pharma ranks better than 73% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 78.0%. The price is 78.0% below its peak now.

What do analysts think of Zealand Pharma?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

73

Quality, value and trend together. Better than 73% of Nordic stocks.

No. 33 of 195 in healthcare

Quality95
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 20 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.03
  • Asset turnoverSales divided by everything the company owns0.31
  • Return on equityProfit divided by equity+26.9%
  • Cash conversionOperating cash flow divided by profit−0.13

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value85
The price · Valuation: the multiples

High Low price: you pay little for what the company earns and owns.

No. 11 of 197 in healthcareTypical in healthcare: 19Typical in the Nordics: 50

  • P/BPrice divided by equity0.8
  • P/SPrice divided by sales2.4
  • P/EPrice divided by earnings3.1
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend7
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 167 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−35.8%
  • 6 months−35.0%
  • 9 months−45.2%
  • 12 months−61.6%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−9.3%
3 years, per year
−9.1%
5 years, per year
+1.0%
10 years, per year
+8.0%
Largest fall, 3 years
−78.0%
From a peak to the bottom
From the peak now
−78.0%
How far the price is from the peak
Volatility, 1 year
63.1%
How much the price swings over a year
Beta, 1 year
1.26
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Zealand Pharma

20 funds we follow own Zealand Pharma. The share is how much of the fund the stock makes up.

  • Norway1
  • Sweden12
  • Denmark7
  • 2 ETFs

From the funds' latest known holdings.

About Zealand Pharma

Zealand Pharma A/S is a company in healthcare, listed on Nasdaq Copenhagen. By market value, Zealand Pharma is number 10 of 20 companies in healthcare on Nasdaq Copenhagen. Zealand Pharma has not paid a dividend in the past twelve months. Of the three measures in the ranking, Zealand Pharma is strongest on quality, better than 95% of Nordic stocks. The next report from Zealand Pharma is expected on 25 February 2027. The share trades in DKK. It has around 600 employees.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism.

See the full analysis of Zealand Pharma.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Copenhagen

Explore the stock market